Key statistics
On Thursday, Entrada Therapeutics Inc (TRDA:NMQ) closed at 10.80, -21.85% below its 52-week high of 13.82, set on Feb 24, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 11.12 |
|---|---|
| High | 11.41 |
| Low | 10.48 |
| Bid | 9.50 |
| Offer | 14.00 |
| Previous close | 11.07 |
| Average volume | 201.75k |
|---|---|
| Shares outstanding | 38.22m |
| Free float | 32.78m |
| P/E (TTM) | -- |
| Market cap | 423.09m USD |
| EPS (TTM) | -2.50 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
Announcements
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
- Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Entrada Therapeutics Reports Third Quarter 2025 Financial Results
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Entrada Therapeutics Reports Second Quarter 2025 Financial Results
- Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
More ▼
